ABSTRACT
Background: Patients undergoing cancer treatment and people with a history of cancer constitute a high-risk patient group in the COVID-19 pandemic. In this study, we aimed to evaluate the life effect of the COVID-19 pandemic on the treatment processes of cancer patients receiving radiotherapy at our hospital's Radiation Oncology Clinic. Methods: Sociodemographic data, COVID-19 pandemic awareness, vaccination and disease transmission of the Radiation Oncology Clinic's patients were administered with a written questionnaire that includes the effects of the pandemic on the treatment between 1st and 30th June of 2021. Results: 7 (13.2%) of the patients had COVID-19 infection during the treatment processes, the in-home index was 4 (57%) due to contact with the case (p<0.001). 4 of the patients (7.5%) stated that they had experienced disruptions in their treatment processes caused by the health institution and 4 of the patients (7.5%) stated that they had experienced disruptions in their treatment processes caused by personal anxiety and anxiety during the pandemic process. 8 patients (15%) stated that they had concerns that they would receive incomplete treatment due to the pandemic process, while one patient (1.9%) stated that they had received psychological support and psychiatric medication due to this anxiety and fear. 9 patients (17%) stated that the covid-19 pandemic had a negative effect on oncological disease treatment processes. Conclusion: It is important that the treatment and follow-up of cancer patients, who are a at-risk group for COVID-19 infection, should continue without interruption, accompanied by up-to-date national and international guidelines.
ABSTRACT
Objective: As of December 2021, two types of vaccines are applied in our country: inactive Coronavac and BNT162b2 mRNA vaccine. In this study, it was aimed to compare the rates of Covid-19 disease infection, pneumonia development rates and hospitalization requirement of individuals vaccinated with different vaccines. Materials and methods: Individuals at least one dose vaccinated with Coronavac inactive or mRNA active were compared for the evaluation of oxygen saturation values, SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) results for the development of pneumonia, and hospitalization. Results: 71 individuals vaccinated with mRNA vaccine and 145 individuals vaccinated with inactive Coronavac vaccine, a total of 216 individuals were evaluated. There was no significant difference between the two groups in terms of the presence of fever complaints and Sars-CoV-2 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) positivity rates. 5.6% (n=4) of the individuals vaccinated with the mRNA vaccine had pneumonic infiltration on non-contrast computed tomography (CT) images of the thorax, while 2.8% (n=2) required hospitalization. 17.9% (n=4) of the individuals vaccinated with inactive Coronavac vaccine had pneumonic infiltration on non-contrast thoracic CT images, while 11.7% (n=17) had hospitalization requirement. Conclusion: There are currently no studies in the literature comparing the effectiveness of an inactive vaccine and an mRNA vaccine. In our study, we concluded that even if people vaccinated with the mRNA vaccine were infected with Sars-CoV-2, the pneumonic involvement and hospitalization requirements for thoracic CT were lower compared to those without the vaccine and those vaccinated with the inactive Coronavac vaccine.
ABSTRACT
Introduction: Coronavirus disease 2019 (COVID-19) is known to have higher morbidity and mortality rates, parallel to the increased risk factors in the elderly. We aimed to define the risk factors related to mortality and morbidity in older patients hospitalized with COVID-19 disease in this study. Materials and Methods: This retrospective cross-sectional study included patients aged ≥65 years who were hospitalized with a confirmed diagnosis of COVID-19. We analyzed their demographic data, clinical findings, comorbidities, laboratory and radiologic findings, treatment protocols, and outcomes. Results: A total of 58 patients were included in the study. A total of eight (13.8%) patients died during the clinical follow-up and treatment, and 50 (86.2%) patients were discharged. The most common comorbidities among all patients were hypertension (HT) (69%) and diabetes mellitus (39.7%). The most common symptoms include fever (51.7%), cough (44.8%), and dyspnea (43.1%), and the most common neurologic findings were headache (27.6%) and impaired consciousness (27.6%). Intensive care unit admission was significantly higher among patients with comorbidities of HT, cerebrovascular disease, atrial fibrillation (AF), and chronic obstructive pulmonary disease. The rate of death was significantly higher in patients with a history of smoking, cerebrovascular disease, AF, and HT. Although there was a statistically significant positive correlation between the death rate and leukocyte, neutrophil, C-reactive protein, lactate dehydrogenase, D-dimer, interleukin-6, and procalcitonin levels, a negative correlation was observed in lymphocyte levels. Conclusion: Age-related comorbid conditions, especially HT, cerebrovascular disease, and AF, caused increased morbidity and mortality rates in older patients with COVID-19.
ABSTRACT
Aim: There is currently no pharmacotherapy with for the treatment of COVID-19. We aimed to investigate the effects of early and high-dose vitamin C (VC) therapy in hospitalized patients with COVID-19. Materials and Methods: We included patients (n=139) who received high-dose VC supplement to the standard treatment protocol into group 1 (n=58), and only those who received a standard treatment protocol into group 2 (n=81). The patients' requirement for supplemental oxygen therapy, requirement for intensive care treatment and survival rates was investigated retrospectively. Furthermore, the changes in white blood cell, C-reactive protein (CRP), procalcitonin, D-Dimer, renal function tests, ferritin, and interleukin 6 values during hospitalization were evaluated.
ABSTRACT
Introduction: Early detection of the severity of COVID-19 disease is important for patient prognosis and effective use of hospital capac- ity. Early detection of critical patients and providing supportive treatment is the main goal of disease management. In this study, we evaluated demographic, clinical, laboratory and radiological findings in COVID-19 patients and aimed to find risk factors associated with poor prognosis. Materials and Methods: A total of 579 cases hospitalized with the diagnosis of COVID-19 were evaluated retrospectively. The diagnosis of COVID-19 was confirmed by polymerase chain reaction (PCR) positivity or typical clinical, laboratory and radiological findings. The study population was divided into groups according to the World Health Organization (WHO) COVID-19 disease severity classification. Significant risk factors associated with severe disease and mortality were investigated by comparing the demographic, clinical, labora- tory and radiological data of these groups. Results: Mean age of the 579 cases was 54 +/- 18.25, and 321 of them (55.4%) were male. Severe disease was detected in 131 (22.6%) patients and mortality rate was %8.29. The most common comorbidities were hypertension (31.8%), diabetes mellitus (18.5%) and coronary artery disease (17.8%), respectively. The most common symptoms at the time of admission to the hospital were cough (40.7%), fever (38 degrees C;33.6%) and shortness of breath (26.3%). Age, coronary artery disease and shortness of breath, neutrophil count, urea, CRP, ferritin, Pro-BNP, fibronogen, IL-6 values were found to be predictive variables for severe disease. Age, presence of shortness of breath, urea, ferritin and Pro-BNP values were found to be independent predictive variables for severe disease, and the cut-off points were calculated for these variables (age 59.5, urea 33.5 mg/dL, ferritin 50.8 mu g/L and Pro-BNP 881 pg/mL). Conclusion: Some predictive factors were demonstrated to detect severe disease in COVID-19 patients. It is important to predict poor prognosis based on these factors. It provides early detection of critical patients and it will be a guide for reducing mortality rates in these patients with effective treatment.
ABSTRACT
Introduction: In this study, we aimed to better understand the role of chest CT as an initial workup tool among all COVID-19 patients admitted to a tertiary hospital. Materials and Methods: We retrospectively evaluated the data of patients that were suspected for COVID-19. All patients who had both noncontrast chest CT scan with RT-PCR test results included in the study. Symptomatic patients were divided into four groups according to time between the onset of symptoms and chest CT;4 days, 5-8 days, 9-13 days, and 14 days. Chest CT findings according to symptom status, duration, and RT-PCR positivity were evaluated. Results: Data for a total of 791 patients were evaluated. The mean patient age was 51.7 19.7 years. 459 (58%) patients were male, and 332 (42%) were female. 55.1% of patients had positive and 44.9% negative RT-PCR tests. Typical, indeterminate, atypical and negative chest CT findings were seen in 241 (30.5%), 131 (16.6%), 154 (19.5%), and 265 (33.5%) patients, respectively. Among 355 patients with negative RT-PCR results, 152 (42.8%) had typical or indeterminate chest CT findings. Asymptomatic patients had a 91.9% of RT-PCR positivity. Only 123 (61.5%) patients had typical or indeterminate CT findings among symptomatic and RT-PCR positive cohort. Conclusion: The greatest value of our study is in demonstrating the value of chest CT in both patients that had symptoms but had negative RT-PCR test results and insignificance of chest CT in asymptomatic but had suspected contact with COVID-19 patients.